Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, two female patients with severe, treatment-resistant alopecia areata showed significant hair regrowth after a single session of intradermal administration of adipose tissue–derived exosomes, without experiencing adverse events, suggesting a promising therapeutic strategy for refractory cases.

This study documented successful use of Brevilin-A, a topical treatment, in pediatric patients with alopecia areata, indicating it as a potentially safe and effective option for managing mild-moderate cases and resistant forms of the disease.

In this study, researchers developed and tested an Italian version of the Skindex-16AA to assess Health-Related Quality of Life in patients with moderate-to-severe Alopecia Areata, emphasizing the importance of patient perception in evaluating their mental health and quality of life.

In this study, researchers identified yellow dots as the most common dermoscopic feature of alopecia areata, followed by black dots, broken hairs, short vellus hair, and tapering hairs.

This study found that methotrexate may be an effective and safe treatment option for severe alopecia areata, with better regrowth results when combined with corticosteroids.

This study recommends limiting routine thyroid function screening to children with alopecia areata who have medical histories of Down syndrome, atopy, or family histories of thyroid disease.

In this Mendelian randomization study, shortened leukocyte telomere length was associated with an increased risk of androgenetic alopecia, but no causal relationship was found with alopecia areata.

This study found that exclamation mark hairs are the only trichoscopic feature that can differentiate clinically suspicious SA from AA.

This retrospective study at the University Clinical Centre in Gdańsk reported that 77.9% of patients with alopecia areata were treated with off-label pharmacotherapy, predominantly glucocorticosteroids, highlighting a reliance on these therapies in European clinical practice.

This abstract provides background information on alopecia areata, describing it as an autoimmune condition leading to non-scarring, patchy hair loss but does not report specific study results.

This study using Mendelian randomization found that higher levels of circulating β-carotene and α-tocopherol may reduce the risk of androgenetic alopecia, while α-tocopherol may also protect against alopecia areata, suggesting diet-derived antioxidants could aid in preventing non-scarring alopecia.

This study suggests that DPCP treatment can be effective and safe for severe alopecia areata in children, with maintenance therapy potentially reducing relapse rates.

This review discusses hairstyling practices in the black community linked to traction alopecia, categorizes them by risk, and offers guidance for dermatologists on management and patient education but reports no new clinical results.

This study found that early-onset patients with alopecia universalis or a family history of alopecia areata showed worse prognosis compared to those with late-onset.

This study found that oral tofacitinib was effective in promoting hair regrowth in patients with alopecia universalis, although further controlled studies are recommended to confirm its safety and efficacy.

In this study, simvastatin/ezetimibe treatment led to partial hair regrowth in about 29% of patients with recalcitrant alopecia areata, suggesting it may be a viable alternative therapy for this condition.

This review highlights the significant negative impact of alopecia areata on quality of life, mental health, and work, calling for individualized approaches and effective treatments to mitigate these effects.

This case study describes severe hypertrichosis in a 3-year-old with alopecia areata after unsupervised use of high-dose topical minoxidil, highlighting the need to avoid such practices in children.

This case report describes two instances of habit tic nail deformities associated with alopecia areata.

In this study, baricitinib was effective in improving hair regrowth in patients with severe alopecia areata over one year, especially when treatment began within four years of symptom onset.

This study reported that in Hispanic/Latinx patients with alopecia areata, rheumatoid arthritis was a common autoimmune comorbidity, and gastroesophageal reflux disease was notably more prevalent than in other populations with alopecia areata.

This study reviewed 20 studies and found that pulse corticosteroid therapy led to complete hair regrowth in 38.53% of patients with severe alopecia areata, but came with many unwanted side effects.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

This study concluded that oral tofacitinib significantly improved hair growth in patients with alopecia areata, alopecia totalis, and alopecia universalis over a 24-week period, but longer studies are needed to assess long-term safety.

This article discusses the clinical features of tumid lupus erythematosus and emphasizes its importance as a differential diagnosis for noncicatricial alopecia, highlighting a case similar to alopecia areata without reporting new clinical results.

This review synthesizes current evidence on alopecia areata, detailing its clinical features, pathogenesis, and treatment options, but does not present new clinical results.

This review discusses prevention, diagnosis, and treatment strategies for traction alopecia but presents no new clinical findings; the authors emphasize early intervention to prevent permanent hair loss.

JAK inhibitors show promise for treating alopecia areata, but more research is needed.

This review discusses the pathogenesis of alopecia areata, highlighting the role of immune privilege collapse in hair follicles but reports no clinical results.

This study found that dysregulation of systemic Th1, Th2, and Th17 cytokines is associated with alopecia areata, with specific cytokines linked to disease activity and treatment response.